C

Cellivery Therapeutics Inc
KOSDAQ:268600

Watchlist Manager
Cellivery Therapeutics Inc
KOSDAQ:268600
Watchlist
Price: 6 680 KRW -29.91% Market Closed
Market Cap: 594.9m KRW

Intrinsic Value

The intrinsic value of one Cellivery Therapeutics Inc stock under the Base Case scenario is 270 079.19 KRW. Compared to the current market price of 6 680 KRW, Cellivery Therapeutics Inc is Undervalued by 98%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

Intrinsic Value
270 079.19 KRW
Undervaluation 98%
Intrinsic Value
Price
C
Worst Case
Base Case
Best Case
Compare Cellivery Therapeutics Inc to

Fundamental Analysis

Cellivery Therapeutics Inc
KOSDAQ:268600
KR
Life Sciences Tools & Services
Market Cap
594.9m KRW
IPO
Nov 9, 2018
KR
Life Sciences Tools & Services
Market Cap
594.9m KRW
IPO
Nov 9, 2018
Price
â‚©
â‚©
Cellivery Therapeutics Inc
Company Overview
Loading...
Economic Moat
Loading...
Contacts
Loading...
How do you feel about Cellivery Therapeutics Inc?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Cellivery Therapeutics Inc

Current Assets 2.9B
Cash & Short-Term Investments 133.8m
Receivables 1.7B
Other Current Assets 1.1B
Non-Current Assets 17.9B
Long-Term Investments 1B
PP&E 16B
Intangibles 365.5m
Other Non-Current Assets 439.4m
Current Liabilities 42.9B
Accounts Payable 301.3m
Accrued Liabilities 7.2B
Short-Term Debt 16.3B
Other Current Liabilities 19.2B
Non-Current Liabilities -1.9B
Long-Term Debt 2.1m
Other Non-Current Liabilities -1.9B
Efficiency

Free Cash Flow Analysis
Cellivery Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Cellivery Therapeutics Inc

Revenue
24.5B KRW
Cost of Revenue
-24B KRW
Gross Profit
563.7m KRW
Operating Expenses
-15.5B KRW
Operating Income
-14.9B KRW
Other Expenses
8.8B KRW
Net Income
-6.1B KRW
Fundamental Scores

Profitability Score
Profitability Due Diligence

Cellivery Therapeutics Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

30/100
Profitability
Score

Cellivery Therapeutics Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

Cellivery Therapeutics Inc's solvency score is 18/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Short-Term Solvency
Positive Net Debt
18/100
Solvency
Score

Cellivery Therapeutics Inc's solvency score is 18/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
Cellivery Therapeutics Inc

There are no price targets for Cellivery Therapeutics Inc.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Dividends

Cellivery Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for Cellivery Therapeutics Inc is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y